Disruptive Technology ChannelCancer Detection & Investing Selection: The ARKG ETFBy Tom LydonJanuary 8, 2021
FeaturedModerna Helps Biotech ETFs Mitigate Massive Losses as Stocks TumbleBy Ian YoungJanuary 4, 2021
Disruptive Technology ChannelDisruption Lurks in 2021. ARKK and ARKG Are Ready For ItBy Tom LydonDecember 30, 2020
Disruptive Technology ChannelThe ARKG ETF Doesn’t Need More Catalysts. It’s Getting Them AnywayBy Tom LydonDecember 15, 2020
Disruptive Technology ChannelFalling Costs Make Genomics (and Their ETFs) More Attractive than EverBy Tom LydonDecember 9, 2020
Disruptive Technology ChannelUp 144% in a Tumultuous 2020? No Surprise for ARKGBy Tom LydonDecember 2, 2020
Disruptive Technology ChannelHow Precision Medicine Will Revolutionize HealthcareBy Tom LydonNovember 25, 2020
Disruptive Technology ChannelBad Ideas: The Industries on Innovation’s Chopping BlockBy Max ChenNovember 17, 2020
Disruptive Technology ChannelThe Genomics ETF on the Front Lines of Cancer DetectionBy Tom LydonNovember 16, 2020
Disruptive Technology ChannelHow CRISPR Future Shapes Up for Hot Genomics ETFBy Tom LydonOctober 15, 2020
Disruptive Technology ChannelLong Read DNA Sequencing Ready for its Moment. That’s Big for this ETFBy Todd ShriberOctober 8, 2020
Thematic Investing ChannelThematic ETF Asset Growth Climbs Even HigherBy Todd RosenbluthOctober 7, 2020
Disruptive Technology ChannelAnother Interesting Week for the Genomics ETFBy Todd ShriberSeptember 28, 2020
Disruptive Technology ChannelDark Genes Shine Light on Genomics ETF OpportunityBy Tom LydonSeptember 23, 2020
